BioSpace News Archive

Sirnaomics Ltd. announced today the interim results from a Phase I clinical trial evaluating the safety, tolerability and anti-tumor activity of the Company’s siRNA (small interfering RNA) drug candidate, STP707 with intravenous (IV) administration in the United States.

BiondVax Pharmaceuticals Ltd. announced the closing of its underwritten public offering with gross proceeds to the Company to be $8,000,000, before deducting underwriting discounts and other expenses payable by the Company.

Asklepios BioPharmaceutical, Inc. (AskBio) today announced that the FDA’s approval of a new adeno-associated virus (AAV) gene therapy to treat adults with hemophilia B marks another milestone for the advancement of AAV therapeutics and highlights the important research contributions made by AskBio Co-Founder, President and Chief Scientific Officer, R. Jude Samulski, PhD.

Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present at the 41st Annual J.P. Morgan Healthcare Conference, which is taking place in San Francisco, CA from January 9 – 12, 2023.

Radius Health, Inc. (“Radius” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved TYMLOS® (abaloparatide), a parathyroid hormone related peptide [PTHrP(1‑34)] analog, as a treatment to increase bone density in men with osteoporosis at high risk of fracture (defined as a history of osteoporotic fracture or multiple risk factors for fracture), or in patients who have failed or are intolerant to other available osteoporosis therapy.

Sharps Technology, Inc., an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, announces they have commenced manufacturing of their much-needed ultra-low waste smart safety syringe products in their European operation in Hungary.

Quantum Leap Healthcare Collaborative (QLHC) today announced that a regimen including oral paclitaxel plus encequidar (Athenex) in combination with a PD-1 inhibitor and carboplatin has graduated in the triple-negative subset of high-risk early-stage breast cancer.

Horizon Therapeutics plc (Nasdaq: HZNP) today announced the Brazilian Health Regulatory Agency (ANVISA) has approved UPLIZNA as a monotherapy for the treatment of adult patients with NMOSD who are AQP4-IgG+.

Cybin Inc. is pleased to provide a year-end summary of its key milestone accomplishments in 2022.

MAIA Biotechnology, Inc. (NYSE American: MAIA ) (“MAIA,” “the Company”) today announced that it completed a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) for the planned U.S. expansion of the THIO-101 Phase 2 trial evaluating THIO, an investigational telomere-targeting agent, in patients with advanced non-small cell lung cancer (NSCLC).